These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 30416292)

  • 1. Efficacy of inhibitory learning theory-based exposure and response prevention and selective serotonin reuptake inhibitor in obsessive-compulsive disorder management: A treatment comparison.
    Samantaray NN; Chaudhury S; Singh P
    Ind Psychiatry J; 2018; 27(1):53-60. PubMed ID: 30416292
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Preliminary Examination of Acceptance and Commitment Therapy Versus Exposure and Response Prevention for Patients with Obsessive-Compulsive Disorder on an Optimal Dose of SSRIs: A Randomized Controlled Trial in Iran.
    Zemestani M; Salavati M; Seyedolshohadayi A; Petersen JM; Ong CW; Twohig MP; Ghaderi E
    Behav Modif; 2022 May; 46(3):553-580. PubMed ID: 33356487
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Early onset of response with selective serotonin reuptake inhibitors in obsessive-compulsive disorder: a meta-analysis.
    Issari Y; Jakubovski E; Bartley CA; Pittenger C; Bloch MH
    J Clin Psychiatry; 2016 May; 77(5):e605-11. PubMed ID: 27249090
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effectiveness of exposure and response prevention combined with pharmacotherapy for obsessive-compulsive disorder: A systematic review and meta-analysis.
    Mao L; Hu M; Luo L; Wu Y; Lu Z; Zou J
    Front Psychiatry; 2022; 13():973838. PubMed ID: 36186855
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Acceptance and Commitment Therapy, Selective Serotonin Reuptake Inhibitors and Their Combination in the Improvement of Obsessive-Compulsive Symptoms and Experiential Avoidance in Patients With Obsessive-Compulsive Disorder.
    Vakili Y; Gharaee B; Habibi M
    Iran J Psychiatry Behav Sci; 2015 Jun; 9(2):e845. PubMed ID: 26288647
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Repetitive transcranial magnetic stimulation (r-TMS) and selective serotonin reuptake inhibitor-resistance in obsessive-compulsive disorder: A meta-analysis and clinical implications.
    Pellegrini L; Garg K; Enara A; Gottlieb DS; Wellsted D; Albert U; Laws KR; Fineberg NA
    Compr Psychiatry; 2022 Oct; 118():152339. PubMed ID: 35917621
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serotonin reuptake inhibitor-cognitive behavioural therapy-second generation antipsychotic combination for severe treatment-resistant obsessive-compulsive disorder. A prospective observational study.
    Tundo A; Salvati L; Cieri L; Balestrini V; Di Spigno D; Orazi F; Iommi M; Necci R
    Int J Psychiatry Clin Pract; 2022 Nov; 26(4):395-400. PubMed ID: 35323098
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Optimal treatment for obsessive compulsive disorder: a randomized controlled feasibility study of the clinical-effectiveness and cost-effectiveness of cognitive-behavioural therapy, selective serotonin reuptake inhibitors and their combination in the management of obsessive compulsive disorder.
    Fineberg NA; Baldwin DS; Drummond LM; Wyatt S; Hanson J; Gopi S; Kaur S; Reid J; Marwah V; Sachdev RA; Pampaloni I; Shahper S; Varlakova Y; Mpavaenda D; Manson C; O'Leary C; Irvine K; Monji-Patel D; Shodunke A; Dyer T; Dymond A; Barton G; Wellsted D
    Int Clin Psychopharmacol; 2018 Nov; 33(6):334-348. PubMed ID: 30113928
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A longitudinal event-related potential study of selective serotonin reuptake inhibitor therapy in treatment-naïve pediatric obsessive compulsive disorder patients.
    Yamamuro K; Ota T; Iida J; Kishimoto N; Nakanishi Y; Matsuura H; Uratani M; Okazaki K; Kishimoto T
    Psychiatry Res; 2016 Nov; 245():217-223. PubMed ID: 27552672
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cognitive-Behavioral Therapy Versus Transcranial Direct Current Stimulation for Augmenting Selective Serotonin Reuptake Inhibitors in Obsessive-Compulsive Disorder Patients.
    Dadashi M; Yousefi Asl V; Morsali Y
    Basic Clin Neurosci; 2020; 11(1):111-120. PubMed ID: 32483481
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibitory learning approaches to exposure therapy: A critical review and translation to obsessive-compulsive disorder.
    Jacoby RJ; Abramowitz JS
    Clin Psychol Rev; 2016 Nov; 49():28-40. PubMed ID: 27521505
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical Effectiveness of N-Methyl-D-Aspartate (NMDA) Receptor Antagonists in Adult Obsessive-Compulsive Disorder (OCD) Treatment: A Systematic Review.
    Ferguson AA; Khan AI; Abuzainah B; Chaudhuri D; Khan KI; Al Shouli R; Allakky A; Hamdan JA
    Cureus; 2023 Apr; 15(4):e37833. PubMed ID: 37213965
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Better than treated as usual: Transcranial magnetic stimulation augmentation in selective serotonin reuptake inhibitor-refractory obsessive-compulsive disorder, mini-review and pilot open-label trial.
    Pallanti S; Marras A; Salerno L; Makris N; Hollander E
    J Psychopharmacol; 2016 Jun; 30(6):568-78. PubMed ID: 26843373
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Psychopharmacological Treatment of Obsessive-Compulsive Disorder (OCD).
    Del Casale A; Sorice S; Padovano A; Simmaco M; Ferracuti S; Lamis DA; Rapinesi C; Sani G; Girardi P; Kotzalidis GD; Pompili M
    Curr Neuropharmacol; 2019; 17(8):710-736. PubMed ID: 30101713
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cognitive-behavior therapy, sertraline, and their combination for children and adolescents with obsessive-compulsive disorder: the Pediatric OCD Treatment Study (POTS) randomized controlled trial.
    Pediatric OCD Treatment Study (POTS) Team
    JAMA; 2004 Oct; 292(16):1969-76. PubMed ID: 15507582
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Systematic Review of Evidence-based Treatment Strategies for Obsessive- compulsive Disorder Resistant to first-line Pharmacotherapy.
    Albert U; Marazziti D; Di Salvo G; Solia F; Rosso G; Maina G
    Curr Med Chem; 2018; 25(41):5647-5661. PubMed ID: 29278206
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Does the addition of cognitive therapy to exposure and response prevention for obsessive compulsive disorder enhance clinical efficacy? A randomized controlled trial in a community setting.
    Rector NA; Richter MA; Katz D; Leybman M
    Br J Clin Psychol; 2019 Mar; 58(1):1-18. PubMed ID: 29984550
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A study of cognitive function in treatment-refractory obsessive-compulsive disorder treated with capsulotomy.
    Gong F; Li P; Li B; Zhang S; Zhang X; Yang S; Liu H; Wang W
    J Neurosurg; 2018 Feb; 128(2):583-595. PubMed ID: 28338440
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A comparative, single-blind, randomized study on quetiapine and aripiperazole augmentation in treatment of selective serotonin reuptake inhibitor refractory obsessive-compulsive disorder.
    Talaei A; Hosseini FF; Aghili Z; Akhondzadeh S; Asadpour E; Mehramiz NJ; Forouzanfar F
    Can J Physiol Pharmacol; 2020 Apr; 98(4):236-242. PubMed ID: 32228235
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A long-term trial of the effectiveness and safety of atypical antipsychotic agents in augmenting SSRI-refractory obsessive-compulsive disorder.
    Matsunaga H; Nagata T; Hayashida K; Ohya K; Kiriike N; Stein DJ
    J Clin Psychiatry; 2009 Jun; 70(6):863-8. PubMed ID: 19422759
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.